Sunshine Biopharma, Inc. (SBFM)

Market Cap	17.98M
Revenue (ttm)	490,878
Net Income (ttm)	-2.57M
Shares Out	22.59M
EPS (ttm)	-5.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,857
Open	0.770
Previous Close	0.790
Day's Range	0.770 - 0.807
52-Week Range	0.620 - 9.870
Beta	-0.87
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2023

About SBFM

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatmen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: SBFM

Financial Performance

In 2021, SBFM's revenue was $228,426, an increase of 219.88% compared to the previous year's $71,410. Losses were -$12.44 million, 346.7% more than in 2020.